Medical & Pharmaceutical Trends Impacting The Chemicals And Materials Industry Feb09
34
Know Your End-Market! Medical & Pharmaceutical Trends Impacting the Chemicals and Materials Industry A panel discussion with Frost & Sullivan's leading Chemicals & Materials analysts: Hariharan Ramasubramanian, Dr Leonidas Dokos 27 February 2009
Medical & Pharmaceutical Trends Impacting The Chemicals And Materials Industry Feb09
1. Know Your End-Market! Medical & Pharmaceutical Trends
Impacting the Chemicals and Materials Industry A panel discussion
with Frost & Sullivan's leading Chemicals & Materials
analysts: Hariharan Ramasubramanian, Dr Leonidas Dokos 27 February
2009
2. Focus Points Introduction Impact of Economic downturn Key
Medical & Pharmaceutical Trends Materials for Medical Devices
Product Segmentation Challenges, Drivers and Growth Chemical
Excipients Product Segmentation Challenges, Drivers and Growth
Major Industry Participants Conclusion 2
3. Introduction 3
4. The Integrated Industry Perspective Healthcare represents a
crucial downstream end-user Coatings, Plastics Adhesives
Performance Specialty and Packaging and Materials Chemicals
Polymers Sealants Aerospace Aerospace Automotive & Automotive
& Automotive & & Defense & Defense Transportation
Transportation Transportation Automotive & Automotive &
Electronics Environment Electronics Transportation Transportation
Electronics Electronics Healthcare Healthcare Environment
Healthcare Healthcare Food Construction Energy Construction
Construction Healthcare Source: Frost & Sullivan Source: Frost
& Sullivan 4
5. The Medical and Pharmaceutical end-use markets for Materials
and Chemicals Healthcare Medical & Pharmaceutical Materials in
Chemicals Excipients for Healthcare Pharmaceutical Drugs Materials
in Materials in Medical Devices Medical Packaging 5
6. Economic Downturn Impact on Medical and Pharmaceutical
Markets 6
7. Impact on Sectors of the Economy Market Indices as an
Indicator for Industry Prospects The effects of the downturn has
disproportionately affected different segments of the economy The
healthcare sector has outperformed the broader market US Market
Indices 16,000 14,000 Indices value (units) 12,000 10,000 8,000
Healthcare Indices, while 6,000 declining, have still 4,000
outperformed Dec-07 Feb-08 Mar-08 May-08 Jul-08 Aug-08 Oct-08
Nov-08 the broader Dow Jones Industrial Average NasDaq Biotech
market NasDaq Financials NASDAQ Transportation S&P HEALTHCARE
INDEX PHLX SEMICONDUCTOR SECTOR INDEX This implies that investors
expect that, while the healthcare sector will be affected by the
downturn, it will still out-perform the general economy 7
8. Winners and Losers High Elite: Companies which have Elite
Winners high cash reserves, but Big Pharma unable to do much to
improve their business because of the unfavorable situation Big
imaging companies Winners: Companies which Financial Leverage Big
device have high cash reserves and companies are able to leverage
this Big IVD situation successfully through Losers Opportunists
strategies like M&A / Small device alliances. companies
Discretionary product manufacturers Generic Opportunists: Companies
manufacturers which have the best Home care opportunity to grow
during the companies economic downturn Low Losers: Companies likely
to High Business risks in economic downturn Low loose their
revenues due to economic downturn Source: Frost & Sullivan
8
9. What is the way forward ? Medical devices becomes a more
attractive segment for plastics suppliers facing declines in their
other key end user segments. The prospects for higher margins and a
stable demand acts as a major incentive for companies to invest.
However, a focussed - rather than piecemeal approach to the market
will be important for companies looking for long term growth in
this segment. Plastics in Medical devices to grow at a CAGR of 5.4%
in the period 2009-2015. Companies such as Invibio (Victrex) and
LyondellBasell that have built up a separate brand image and
identity for their medical products are well placed to grow in this
segment 9
10. What is the way forward ? (contd) As the era of blockbuster
drugs continues to approach its end, the smaller and specialist
companies are better placed for survival. The pharmaceutical
industry is more apprehensive about the upcoming expirations of
patented drugs than the global economic contraction. The expiration
of patents means that manufacturers of excipients need to be
prepared to do business with a larger number of companies in a
wider geographical spread and at a more cost-driven supply basis.
Strategic partnerships and alliances will become more In over 23
years in the industry, crucial than ever. I've never really seen
pharma Even amidst the current sales being affected by an
challenging economic climate economic downturn in the the market
for pharmaceutical western world. We're probably excipients will
perform better one of the industries that will be than other
chemicals markets affected the last and the least.quot; with a
forecast CAGR CEO of one of worlds top 30 between 2009-2015 of
3.3%. pharma companies. 10
11. Key Medical & Pharmaceutical Drivers and Trends Doctor,
I feel a pain in 11
12. Pharmaceutical trends with Respect to Chemicals &
Materials what lies ahead In 2000, 10% (606 million) of the global
population was aged 60+. By 2050 this will be more than 21% (2
billion). The aging of population and the need for more medical
devices and sophisticated drugs will create undisputedly more
demand for materials, active ingredients and chemical excipients.
There is increasing competition from low-cost manufacturers. These
are located in Asia, especially in India and China, and are
continuously enlarging their capacity while improving at the same
time the quality, credibility and reliability. Source: Frost &
Sullivan 12
13. Pharmaceutical trends with Respect to Chemicals &
Materials what lies ahead (contd) Global mortality from chronic
diseases will increase 50% by 2025. Cardiovascular diseases will
remain the main global mortality chronic disease by 2025 with
cancer and respiratory diseases increasingly affecting more people.
75% of people aged 60+ have one chronic condition, while 50% have
two or more chronic conditions. Chronic diseases account for more
than 60% of all health care spending. Source: Frost & Sullivan
13
14. Performance Material Trends in the Medical Devices and
Pharma Packaging Markets 14
15. Market Segmentation Plastics in Medical Devices Plastics in
Medical Devices Polypropylene Polyethylene PVC Eng Plastics
Syringes Syringe Plungers Catheters Surgical Equipment Labware
Labware Medical Bags Sterilisation Medical Bags Medical Bags
Administration Trays Sets Administration Medical Device Sets
Housings Implants 15
16. Key Themes in the Performance Materials Industry Trends of
Specific Importance to the Medical Device Industry Performance
Materials Market: Impact of Key Industry Themes, Performance
Materials Market: Impact of Key Industry Themes, 2009 2009 10 10
Key selling points for Security Conservation of Security
Conservation of engineering and high Safety resources Safety
resources performance plastics Market Impact Market Impact
Performance Performance Lifestyle trends Lifestyle trends
Differentiation 5 Differentiation 5 Multiple Technical and Service
Multiple functionalities Differentiation functionalities
Sustainable Sustainable production production Expansion PVC
Replacement Expansion 0 0 0 5 Supply chain 10 0 5 Supply chain 10
Internal Impact Internal Impact Source: Frost & Sullivan
Source: Frost & Sullivan Key Trends with High Impact on the
Medical Devices Market 16
17. Key Themes in the Performance Materials Industry (Contd)
Changing Lifestyle Trends 2005 Patient Driven Secondary Care
Available personalised healthcare and choice 2010 Changes in the
Patient knowledge through multiple Changes in for demand the
Primary Care channels demand healthcare for healthcare diagnostics
diagnostics Public pressure on government 2015 One stop shop Home
Care/ Self Testing Consumer responsive providers, products and
services Source: Frost & Sullivan Implications for Material
Selection Demand Volume Unique design principles required
Affordability High robustness required off the device Waiting Lists
Aesthetics also assume higher Public Anxiety importance Development
of demand Opportunities are created therefore for engineering
plastics in these management policies and strategies applications
e.g. demand driven financing 17
18. European Markets for Plastics in Medical Devices Strong
Growth Prospects Revenues forecast to grow at a CAGR of 6.2% in the
period 2008-15 Plastics in Medical Devices: Volume and Revenue
Forecasts (Europe), 2005-2015 350.0 800.0 300.0 700.0 600.0 250.0
Million 500.0 200.0 kt 400.0 150.0 300.0 100.0 200.0 50.0 100.0 0.0
0.0 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 Source:
Frost & Sullivan 18
19. Plastics in Medical Devices Market: For Plastics Suppliers
Developing Relationships with Key End User Groups is Crucial to
Success Direct supply is Polymer Suppliers LyondellBasell the most
preferred route Compounding RTP Compounding Gerresheimer Tier 1
Component Producers Wilden High influence on material selection
Pharma Companies and often specify Boehringer materials to be
Ingelheim used Note: company names are intended Source: Frost &
Sullivan as examples only and do not represent real relationships
19
20. Plastics in Medical Packaging: The Pharmaceutical Blisters
Market Excerpt Key Market Segments The Pharmaceutical Blisters
Market Example Containers Strong Drivers for Growth Vials &
Ampoules Blister Packs Sachets & Strips Blister Market Cost
Efficiency Container Tubes of High Growth Pre-fillable Syringes
Volume Restraints Containers Key Growth Drivers Growth in
Combination Drugs Increase Source: MediSeal in Calendared
Increasing Smart Efforts in Packaging Growth in Drug Anti- The
pharmaceutical Increasing Counterfeiting Compliance blisters market
is Regulations for Efforts Increasing Compliance Drivers expected
to grow at a Barrier Requirements CAGR of 6.6% in the period
2008-14 2008 2014 and beyond Source: Frost & Sullivan 20
21. Frost & Sullivan Studies in the Area Plastics in
Medical Devices Medical Packaging European Markets for Plastics in
European Markets for Pharma Medical Devices M348 - Feb, 09
Packaging M137 Apr, 09 U.S. Markets for Plastics in Medical
Materials for Medical Packaging TI Devices N540 Apr, 09 D0E9 Dec,
07 U.S. Polymers in Medical Tubings and Catheters N498 Jan, 09
Western European Medical Silicones Markets M04A Nov, 06 End Market
Studies of Interest Medical Devices IRG US Infusion Pumps Market
N3A5 - Feb, 09 European Insulin Delivery Devices Market M2CD Oct,
08 Others.. 21
22. Chemical Excipients for the Pharmaceutical Industry Product
Segmentation 22
23. Pharmaceutical trends with Respect to Chemicals the
expected shift New opportunities in the global pharmaceutical
market will appear as the business and market models are evolving.
Liposomal technologies have the potential to increase the
effectiveness of compounds especially in the anti-cancer,
neurological and anti-fungal drug areas. By 2015 opportunities will
Pre 2005 be more prominent in niche Blockbuster Model drugs and
research and development. 2015 Opportunities By 2020 integrated in
the Global Niche Drugs and R&D Pharma packages of products and
Market services will focus on patient 2020 monitoring &
compliance. Integration & Supply Chain Integration of pharma,
diagnostics, medical devices, Source: Frost & Sullivan patient
monitoring and healthcare IT. 23
24. Introduction to Chemical Excipients for Pharmaceuticals
Excipients are inactive ingredients used to formulate active
ingredients into finished dosage forms. Excipients are used to:
provide a matrix in which the drug can be handled control rate of
dosage aid in the processing of the drug delivery system during its
manufacture protect, support or enhance stability, bioavailability
or patient acceptability assist in product identification enhance
any other attribute of the overall safety, effectiveness or
delivery of the drug during storage or use improve comfort when
taking drug such ease of swallowing and better taste 24
26. Major Challenges The global adoption of Current Good
Manufacturing Practices (cGMPs) is the major challenge for this
industry representing the required total commitment of a company to
a set of regulations, codes, and guidelines for the highest
possible quality in manufacture of drugs, medical devices,
diagnostic products, food products and Active Pharmaceutical
Ingredients (APIs). Asian companies are trying to incorporate cGMPs
with various degrees of success. Since 2004, several blockbuster
drugs have lost patent protection and this trend is expected to
become more prominent up to 2011. Source: Colorcon The active
promotion of generics as a high- quality low-expense alternative is
expected to widen the market base for these products. Source:
Innercap Technologies 26
27. Major Drivers The fastest growing region is Asia, due to
its growing economy, and continued improvement in the health care
system. The changing attitude of pharmaceutical industry towards
excipients considering them more than just inactive ingredients but
crucial in improving the performance of the end-product (medicinal
drug). The outsourcing of services in the pharmaceutical industry
is growing. The reasons include the declining investments in
research and development (R&D), increasing generic penetration,
and the growing development costs. Modern contract manufacturing
organisations (CMOs) offer a wide range of services ranging from
pre-clinical development to commercial batch manufacturing to
active/non-active manufacturing, as well as packaging and
distribution. Smooth delivery of a consistent dosage over time is
the objective, with the need for fewer administrations, optimal use
of the delivered drug, and increased patient compliance with the
treatment programme. 27
28. The global pharmaceutical excipients market will perform
better than other chemicals markets The downturn in growth is
expected to last throughout 2009 and 2010 affecting at a different
degree different regions. The market is expected to return to
previous level of activities and growth from 2011. Even amidst the
current challenging economic climate the market for pharmaceutical
excipients will perform better than other chemicals markets. The
CAGR of the period 2009-2015 will be 3.3%. Source: Frost &
Sullivan 28
29. Technologically advanced excipients and environmentally
friendly products will grow faster than commoditised excipients The
Global Pharmaceutical Excipients market is valued at $2.28 billion
and was divided among the following excipients market segments as
shown below. The market for pharmaceutical excipients will perform
better than other chemicals markets. Binders represent the largest
market segment, albeit mostly including commoditised products.
Disintegrants are expected to exhibit a CAGR of 4.6% during the
period 2009-2015. The market for controlled- release
pharmaceuticals is growing rapidly with companies increasingly
turning to drug delivery technologies as a means of expanding
product lifecycles, enhancing drug efficacy and maximizing
revenues. Source: Frost & Sullivan 29
30. Major Industry Participants Pharmaceutical Excipients -
Materials for Medical Applications 30
31. Conclusion The healthcare sector (medical &
pharmaceutical) continues to provide opportunities for innovative
companies, even in the current economic scenario Companies willing
to enter/strengthen their position in the market will however have
to invest in developing the R&D capabilities, and also strong
business development and technical service teams to cater to this
segment In the pharmaceuticals segment, industry participants need
to forge business relationships with generics manufacturers and
align accordingly their distribution networks. Individual markets
researched by Frost & Sullivan recently including the plastics
in medical devices and packaging and the global pharmaceutical
excipients are all showing excellent potential for market
participants 31
32. Next Steps Register for Frost & Sullivans Growth
Opportunity Newsletter and keep abreast of innovative growth
opportunities (www.frost.com/news) Register for the next Chairmans
Series on Growth: (www.frost.com/growthEU) Join us at our 3rd
Annual Customer Contact Executive MindXchange (June 2009, Europe)
Join us in London on 19 20 May at Growth, Innovation and Leadership
2009: A Frost & Sullivan Global Congress on Corporate Growth
Event (www.frost.com/giluk) Request a proposal for a Growth
Partnership Service to support you and your team to accelerate the
growth of your company. 32
33. Your Feedback is Important to Us What would you like to see
from Frost & Sullivan? Growth Forecasts? Competitive Structure?
Emerging Trends? Strategic Recommendations? Other? Please inform us
by taking our survey. 33
34. For Additional Information Steve Lee Strategic Account
Manager Chemicals, Materials and Food, Asia Pacific (65) 6890 0914
[email protected] Medical & Pharmaceutical Trends Impacting
the Chemicals and Materials Industry 34